Anfasil 50 mg/5 ml (Powder for Suspension)

35 ml bottle: ৳ 75.28

Medicine Details

Category Details
Generic Fluconazole
Company Silva pharmaceuticals ltd
Also available as
Anfasil 50 mg tablet Anfasil 150 mg tablet

Title

  • Anfasil Antifungal Medicine

Categories

  • Medicine
  • Health & Wellness
  • Pharmaceutical

Description

  • Anfasil is a triazole antifungal agent used to treat various fungal infections, including Vaginal Candidiasis, Oropharyngeal Candidiasis, Oesophageal Candidiasis, Tinea corporis, Tinea cruris, Tinea pedis, Kerion, Pityriasis versicolor, Onychomycosis, Invasive candidal infections, Cryptococcal infections, Prevention of cryptococcal meningitis, Prevention of fungal infections in immunocompromised patients, Systemic Candidiasis, Fungal urinary tract infections, Disseminated candidiasis, Prophylaxis for fungal infection in neutropenic cancer patients, Acute treatment of other systemic fungal infections such as coccidioidomycosis and histoplasmosis.

Dimensions

  • N/A

Color Options

  • N/A

Functions

  • Treating fungal infections
  • Inhibiting fungal cytochrome P-450 dependent enzymes
  • Preventing cryptococcal meningitis
  • Prevention of fungal infections in immunocompromised patients

Materials

  • Triazole antifungal agent
  • Fluconazole

Technical Specifications

  • Potent inhibitor of fungal cytochrome P-450 dependent enzymes
  • Essential component of fungal cell membrane responsible for the synthesis of ergosterol

Design Elements

  • N/A

Usability Features

  • Single dose administration for some indications
  • Multiple dose therapy for specific age groups
  • Dosing adjustments for renal impairment
  • Excreted predominantly in urine
  • Requires normal dose with no evidence of renal impairment

Indications

  • Vaginal Candidiasis
  • Oropharyngeal Candidiasis
  • Oesophageal Candidiasis
  • Tinea corporis, Tinea cruris, Tinea pedis, Other Tinea
  • Kerion
  • Pityriasis versicolor
  • Onychomycosis
  • Invasive candidal infections
  • Cryptococcal infections
  • Prevention of cryptococcal meningitis
  • Prevention of fungal infections in immunocompromised patients
  • Systemic Candidiasis
  • Fungal urinary tract infections
  • Disseminated candidiasis
  • Prophylaxis for fungal infection in neutropenic cancer patients
  • Acute treatment of other systemic fungal infections such as coccidioidomycosis and histoplasmosis

Pharmacology

  • Potent inhibitor of fungal cytochrome P-450 dependent enzymes
  • Responsible for the synthesis of ergosterol

Dosage & Administration

  • Adults - varying doses depending on indication
  • Child over 1 year - specific doses based on weight
  • Use in Specific Population - dosing adjustments for elderly, renal impairment, and children

Interaction

  • Increased prothrombin time after warfarin administration
  • Prolonged serum half-life of concomitantly administered oral sulphonylureas
  • Increased plasma concentrations of fluconazole with co-administration of hydrochlorothiazide
  • Increase in the level of phenytoin with concomitant administration of fluconazole
  • Decrease in the AUC and shorter half-life of fluconazole with rifampicin administration
  • No clinically significant impairment of fluconazole absorption when co-administered with food, cimetidine, antacids, or post bone marrow transplantation
  • Decrease in the mean plasma clearance of theophylline
  • Possible drug-drug interactions not tested

Contraindications

  • Known hypersensitivity to fluconazole or related triazole compounds

Side Effects

  • Nausea
  • Abdominal discomfort
  • Diarrhoea
  • Flatulence
  • Rarely encountered adverse events like rash
  • Reported cases of anaphylaxis

Pregnancy & Lactation

  • Adverse fetal effects seen in animals only at high dose levels
  • Recommendation against use in pregnancy or in women of childbearing potential without adequate contraception

Precautions & Warnings

  • Observation of abnormalities in hepatic, renal, haematological, and other biochemical function tests in some patients
  • Rare post-mortem findings of hepatic necrosis
  • Rare development of exfoliative cutaneous reactions such as Stevens Johnson Syndrome and toxic epidermal necrolysis
  • Recommendation to discontinue therapy if a rash develops, especially in patients with invasive/systemic fungal infections
  • Not recommended during lactation

Use in Special Populations

  • Elderly - use normal dose if no evidence of renal impairment
  • Renal Impairment - dosing adjustments based on creatinine clearance
  • Excretion predominantly in urine

Overdose Effects

  • Supportive measures and symptomatic treatment
  • Forced volume diuresis to increase elimination rate
  • Haemodialysis to decrease plasma levels

Related Brands